UKRAINS'KYI VISNYK PSYKHONEVROLOHII

The Scientific and Practical Journal of Medicine
ISSN 2079-0325(p)
DOI 10.36927/2079-0325
Home » Archive of numbers » 2022 » Volume 30, issue 1 (110) » PROTOCOL FOR THE TREATMENT OF PATIENTS WITH MULTIPLE SCLEROSIS BY INJECTION OF BONE MARROW STROMAL CELLS (BCMC) IN THE CONDITIONS OF THE INSTITUTE OF NEUROLOGY, PSYCHIATRY AND NARCOLOGY OF THE NSAN OF UKRAINE

PROTOCOL FOR THE TREATMENT OF PATIENTS WITH MULTIPLE SCLEROSIS BY INJECTION OF BONE MARROW STROMAL CELLS (BCMC) IN THE CONDITIONS OF THE INSTITUTE OF NEUROLOGY, PSYCHIATRY AND NARCOLOGY OF THE NSAN OF UKRAINE

Authors

Type of Article

  • Scientific Article

In the Section

  • TO HELP A PRACTICING PHYSICIAN
Index UDK:

Abstract

diagnosis multiple sclerosis
Code for ICH 10: G35.0.
Patient category: хворі на РС.
Recognition protocol for doctors who treat patients with MS.
Meta Protocol: creation of an algorithm for MS therapy by injecting bone marrow stromal cells (BMSCs), slowing down inflammation, disease progression, and reducing the disability of MS patients.

Pages

  • 85-90

Year / Issue

Download PDF

References

  1. Multiple sclerosis in Ukraine: a personalized treatment strategy / Muratova T.M., Negrych T.I., Voloshyna N.P. [et al. 2020. № 2. С. 14-16. URL: https://health-ua.com/multimedia/5/0/2/7/4/1593093235.pdf.
  2. Disease Progression in Multiple Sclerosis: A Literature Review Exploring Patient Perspectives / E. G. Celius, H. Thompson, M. Pontaga [et. al.]  // Patient Prefer Adherence. 2021. Vol. 15. P. 15—27. DOI: https://doi.org/10.2147/PPA.S268829.
  3. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis / X. Montalban, R. Gold, A. J. Thompson [et al.] // Mult. Scler. 2018. No. 24(2). Р. 96—120. DOI: https://doi.org/10.1177/1352458517751049.
  4. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial / H. P. Hartung, R. Gonsette, N. Konig [et al.] // Lancet. 2002. No. 360  (9350). Р.  2018—2025. DOI: https://doi.org/10.1016/S0140-6736(02)12023-X.
  5. Ocrelizumab versus placebo in primary progressive multiple sclerosis / X. Montalban, S. L. Hauser, L. Kappos [et al.] // N Engl J Med. 2017. No. 376 (3). Р. 209—210. DOI: https://doi.org/10.1056/NEJMoa1606468.
  6. Multilineage potential of adult human mesenchymal stem cells / M. F. Pittenger, A. M. Mackay, S. C. Beck [et al.] // Science. 1999. Vol. 284. Р. 143—147. DOI: https://doi.org/10.1126/science.284.5411.143.
  7. Human mesenchymal stem cells express neural genes, suggesting a neural predisposition / N. R. Blondheim, Y. S. Levy, T. Ben-Zur [ et  ]  // Stem Cells Dev.  2006. Vol.  15, no.  2. Р. 141—164. DOI: https://doi.org/10.1089/scd.2006.15.141.
  8. Kassis I. Bone marrow mesenchymal stem cells: agents of immunomodulation and neuroprotection / I. Kassis, A. VakninDembinsky, D. Karussis // Curr Stem Cell Res Ther. 2011. Vol. 6, Issue 1. Р. 63—68. DOI: https://doi.org/10.2174/157488811794480762.
  9. Uccelli A. Mesenchymal stem cells: a new strategy for immunosuppression? / A.  Uccelli, V.  Pistoia, L.  Moretta  // Trends Immunol.  Vol.  28, Issue  5. Р.  219—226. DOI: https://doi.org/10.1016/j.it.2007.03.001.
  10. Ben-Hur T. Immunomodulation by neural stem cells / T. Ben-Hur // J Neurol Sci. 2008. No. 265 (1—2). Р. 102—104. DOI: https://doi.org/10.1016/j.jns.2007.05.007.
  11. Nauta A. J. Immunomodulatory properties of mesenchymal stromal cells / A. J. Nauta, W. E. Fibbe // Blood. 2007. No. 110 (10). Р. 3499—3506. DOI: https://doi.org/10.1182/blood-2007-02-069716.
  12. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis / I. Kassis, N. Grigoriadis, B. Gowda-Kurkalli [et al.] // Arch Neurol. 2008. No. 65 (6). Р. 753—761. DOI: https://doi.org/10.1001/archneur.65.6.753.
  13. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy / E. Zappia, S. Casazza, E. Pedemonte [et al.] // Blood. 2005. Vol. 106, Issue 5. Р. 1755—1761. DOI: https://doi.org/10.1182/blood-2005-04-1496.
  14. Uccelli A. Mesenchymal stem cells in health and disease / A. Uccelli, L. Moretta, V.  Pistoia  //  Nat  Rev    2008. No. 8 (9). Р. 726—736. DOI: https://doi.org/10.1038/nri2395.
  15. Clinical and pathological effects of intrathecal injection of mesenchymal stem cell-derived neural progenitors in an experimental model of multiple sclerosis / V. K. Harris, Q. J. Yan, T. Vyshkina [ et al.] // J Neurol Sci. 2012. No. 313 (1-2). Р. 167—177. DOI: https://doi.org/10.1016/j.jns.2011.08.036.
  16. Uccelli A. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases / A. Uccelli, A. Laroni, M. S. Freedman // Lancet Neurol. 2011. No. 10 (7). Р. 649—656. DOI: https://doi.org/10.1016/S1474-4422(11)70121-1.
  17. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis / S. Pluchino, A. Quattrini, E. Brambilla [et al.] // Nature. 2003. 422: 688—94. DOI: https://doi.org/10.1038/nature01552.
  18. Human neural stem cells ameliorate autoimmune encephalomyelitis in non-human primates / S. Pluchino, E. Blezer, S. Amadio [et al.] // Ann Neurol. 2009. No. 66 (3). P. 343—354. DOI: https://doi.org/10.1002/ana.21745.
  19. Transplanted multipotential neural precursor cells migrate into the inflamed white matter in response to experimental autoimmune encephalomyelitis / T. Ben-Hur, O. Einstein, R. Mizrachi-Kol [et al.] // Glia. 2003. Vol. 41, Issue 1. Р. 73—80. DOI: https://doi.org/10.1002/glia.10159.
  20. Karussis D. Clinical experience with stem cells and other cell therapies in neurological diseases / D. Karussis, P. Petrou, I. Kassis // J Neurol Sci. 2013. Vol. 324. Р. 1—9. DOI: https://doi.org/10.1016/j.jns.2012.09.031.
  21. Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats / J. Chen, Y. Li, L. Wang, M. Lu [et al.] // J Neurol Sci. 2001. Vol. 189. Р. 49—57. DOI: https://doi.org/10.1016/S0022-510X(01)00557-3.
  22. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis / D. Karussis, C. Karageorgiou, A. Vaknin-Dembinsky [et ]  // Arch Neurol.  2010. 67  (10). Р. 1187—1194. DOI: https://doi.org/10.1001/archneurol.2010.248.
  23. A randomized trial of mesenchymal stem cells in multiple system atrophy / P. H. Lee, J. E. Lee, H. S. Kim [et al.] // Ann Neurol. 2012. 72 (1). Р. 32—40. DOI: https://doi.org/10.1002/ana.23612.
  24. Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: results of phase 1/2 and 2a clinical trials / P. Petrou, Y. Gothelf, Z. Argov [et al.] // JAMA Neurol. 2016. 73 (3). Р. 337—344. DOI: https://doi.org/10.1001/jamaneurol.2015.4321.
  25. NurOwn, phase 2, randomized, clinical trial in patients with ALS: safety, clinical, biomarker results / J. D. Berry, M. E. Cudkowicz, A. J. Windebank [et al.] // Neurology. 2019. 93 (24). Р. 2294—2305. DOI: https://doi.org/10.1212/WNL.0000000000008620.
  26. Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): a proposed treatment for multiple sclerosis and other neuroimmunological/neurodegenerative diseases / [D. Karussis, I. Kassis, B. G. Kurkalli, S. Slavin] // J Neurol Sci. 2008. Vol. 265, Issues 1—2. 265. Р. 131—135. DOI: https://doi.org/10.1016/j.jns.2007.05.005.
  27. Transplantation of spinal cord-derived neural stem cells for ALS: analysis of phase 1 and 2 trials / J. D. Glass, V. S. Hertzberg, N. M. Boulis [et al.] // Neurology. 2016. 87 (4). Р. 392—400. DOI: https://doi.org/10.1212/WNL.0000000000002889.
  28. Voloshina N. P., Vasilovskiy V. V., Mikulinskiy Yu. E., Schegelskaya E. A. Autoterapiya kletkami stromyi kostnogo mozga (KSKM), indutsirovannyimi v nervnyie, bolnyih s hronicheskimi zabolevaniyami TsNS (rasseyannyiy skleroz, bolezn Parkinsona). Ukrainskyi neirokhirurhichnyi zhurnal. 2003. No. 3. URL: https://cyberleninka.ru/article/n/autoterapiya-kletkamistromy-kostnogo-mozga-indutsirovannymi-v-nervnye-bolnyhs-hronicheskimi-zabolevaniyami-tsns-rasseyannyy-skleroz.
  29. Phase I trial of intrathecal mesenchymal stem cellderived neural progenitors in progressive multiple sclerosis / V. K. Harris, J. Stark, T. Vyshkina [et al.] // EBioMedicine. 2018. No. 29. Р. 23—30. DOI: https://doi.org/10.1016/j.ebiom.2018.02.002.
  30. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion / E. Eggenhofer, V. Benseler, A. Kroemer [et al.] // Front Immunol. 2012. No. 3. Р. 297. DOI: https://doi.org/10.3389/fimmu.2012.00297.
  31. Voloshyna N. P., Vasylovskyi V. V., Mikulynskyi Yu. Yu., Shchehelska O. A. Patent UA 68711 A. «Sposib likuvannia khvorykh na rozsiianyi skleroz» vid 02.10.2003. Kyiv. Ukrpatent.
  32. Voloshina N. P., Vasilovskiy V. V. Eticheskie voprosyi v lechenii bolnyih rasseyannyim sklerozom (autoterapiya stromalnyimi kletkami kostnogo mozga, indutsirovannyimi v nervnyie). Kultura narodov Prichernomorya. 2004. No. 56. T. 2. R. 185—186.
  33. Karussis D. The potential use of stem cells in multiple sclerosis: an overview of the preclinical experience / D. Karussis, I. Kassis // Clin Neurol Neurosurg. 2008. No.  110  (9). Р. 889—896. DOI: https://doi.org/10.1016/j.clineuro.2008.02.008.
  34. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study / P. M. Connick, C. Crawley, D. J. Webber [et al.] // Lancet Neurol. 2012. No. 11 (2). Р. 150— 156. DOI: https://doi.org/10.1016/S1474-4422(11)70305-2.
  35. Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: a triple blinded, placebo controlled, randomized phase I/II safety and feasibility study / O. Fernandez, G. Izquierdo, V. Fernandez [et al.] // PLoS ONE. 2018. No. 13 (5): e0195891. DOI: https://doi.org/10.1371/journal.pone.0195891.
  36. Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis / S. Llufriu, M. Sepulveda, Y. Blanco [et al.] // PLoS ONE. 2014. No. 9 (12): e113936. DOI: https://doi.org/10.1371/journal.pone.0113936.
  37. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebocontrolled, multiple-dose study / F.   Lublin, J.  D.  Bowen, J. Huddlestone [et al.] // Mult Scler Relat Disord. 2014. Vol. 3, Issue 6. Р. 696—704. DOI: https://doi.org/10.1016/j.msard.2014.08.002.
  38. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis / P. Petrou, I. Kassis, N. Levin [et al.] // Brain. 2020. No. 143 (12). Р. 3574—3588. DOI: https://doi.org/10.1093/brain/awaa333.
  39. Inflammatory cortical demyelination in early multiple sclerosis / C. F. Lucchinetti, B. F. Popescu, R. F. Bunyan [et al.] // J Med. 2011. No. 365 (23). Р. 2188—2197. DOI: https://doi.org/10.1056/NEJMoa1100648.
  40. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology / R.  Magliozzi, O.  Howell, A. Vora [et  ]  // Brain.  2007. No.  130 (Pt.  4). Р.  1089—1104. DOI: https://doi.org/10.1093/brain/awm038.
  41. Reich D. S. Multiple sclerosis / D. S. Reich, C. F. Lucchinetti, and P. A. Calabresi // J Med. 2018. No. 378 (2). Р. 169—180. DOI: https://doi.org/10.1056/NEJMra1401483.
  42. The molecular basis for remyelination failure in multiple sclerosis / J. Gruchot, V. Weyers, P. Gottle [et al.] // Cells. 2019. No. 8 (8). Р. 825. DOI: https://doi.org/10.3390/cells8080825.
  43. Karussis D. Immunotherapy of multiple sclerosis: the state of the art // BioDrugs. 2013. No. 27 (2). Р. 113—148. DOI: https://doi.org/10.1007/s40259-013-0011-z.
  44. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group / M. S. Freedman, A. Bar-Or, H. L. Atkins [et al.] // Mult Scler. 2010. No. 16 (4). Р. 503—510. DOI: https://doi.org/10.1177/1352458509359727.
  45. International Conference on Cell-Based Therapies for Multiple Sclerosis. Cell-based therapeutic strategies for multiple sclerosis / N.   Scolding, M.  Pasquini, S.  C.  Reingold, J. A. Cohen // Brain. 2017. Vol. 140, Issue 11. Р. 2776—2796. DOI: https://doi.org/10.1093/brain/awx154.
  46. Pluchino S. The therapeutic plasticity of neural stem/ precursor cells in multiple sclerosis / S. Pluchino, G. Martino // J Neurol Sci. 2008. No. 265 (1-2). Р. 105—110. DOI: https://doi.org/10.1016/j.jns.2007.07.020.
  47. Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis / N. H. Riordan, I. Morales, G. Fernandez [et al.] // J Transl Med. 2018. No. 16 (1). Р. 57. DOI: https://doi.org/10.1186/s12967-018-1433-7.

Journal’s Indexing:

UKRAINS'KYI VISNYK PSYKHONEVROLOHII

The Scientific and Practical Journal of Medicine

ДУ «ІНПН імені
П.В. ВОЛОШИНА
НАМН УКРАЇНИ»